Advertisement

Topics

CAR T-cell Therapy for Solid Tumors?

08:00 EDT 5th October 2018 | BioPortfolio

Summary of "CAR T-cell Therapy for Solid Tumors?"

Scientists have identified a wide variety of challenges preventing the development of effective CAR T-cell therapies for solid tumors, but they are investigating just as many potential solutions. Progress has been slow, but many researchers remain optimistic that successful CAR T-cell therapies, either alone or in combination with other treatments, will eventually be developed.

Affiliation

Journal Details

This article was published in the following journal.

Name: Cancer discovery
ISSN: 2159-8290
Pages:

Links

DeepDyve research library

PubMed Articles [27772 Associated PubMed Articles listed on BioPortfolio]

CD28-ζ CAR T Cells Resist TGF-β Repression through IL-2 Signaling, Which Can Be Mimicked by an Engineered IL-7 Autocrine Loop.

Adoptive cell therapy with chimeric antigen receptor (CAR)-redirected T cells induced spectacular regressions of leukemia and lymphoma, however, failed so far in the treatment of solid tumors. A caus...

Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies.

Chimeric antigen receptor (CAR) T-cell therapy, an emerging immunotherapy, has demonstrated promising clinical results in hematological malignancies including B-cell malignancies. However, accessibili...

Animal Models for Studying Tumor Microenvironment (TME) and Resistance to Lymphocytic Infiltration.

In cancer immunotherapy, cytotoxic T or NK cells need to engage cancer cells to initiate the killing. However, in clinical studies and in mouse models, some solid tumors are found with no lymphocytes....

Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery.

Adoptive cell therapy (ACT) with antigen-specific T cells has shown remarkable clinical success; however, approaches to safely and effectively augment T cell function, especially in solid tumors, rema...

Multiple functions of Ikaros in hematological malignancies, solid tumor and autoimmune diseases.

Ikaros, encoded by IKZF1 (Ikaros family zinc finger 1), is an important transcription factor in the control of lymphocyte specification and differentiation. Multiple functions of Ikaros have been exer...

Clinical Trials [13006 Associated Clinical Trials listed on BioPortfolio]

Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 (rIL-2) for Metastatic Solid Tumors

The present protocol is designed to investigate the potential application of allogeneic cell-mediated immunotherapy in metastatic solid tumors similarly to the well established graft versu...

A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors

The proposed clinical trial is a phase I, open-label, multi-center, dose-escalation study of ALT-803 in patients with surgically incurable advanced solid tumors: melanoma, renal cell, non-...

Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung Cancer

This study will determine the maximum tolerated dose (MTD) of NC 6004 in combination with gemcitabine and evaluate the activity, safety, and tolerability of NC- 6004 in combination with ge...

Multiple Target Antigen Stimulating Cell Therapy (MASCT-I) Treatment for Advanced Evil Solid Tumor

Multiple Target Antigen Stimulating Cell Therapy (MASCT-I) is a new immunotherapy that dendritic cells(DC) was induced from autologous peripheral blood. The DC can then be loaded with anti...

Trial of Lenvatinib Plus Pembrolizumab in Subjects With Selected Solid Tumors

This is an open-label Phase 1b study designed to confirm the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with selected solid tumors (non-small c...

Medical and Biotech [MESH] Definitions

Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.

An alkylating agent of value against both hematologic malignancies and solid tumors.

A carbonic anhydrase and transmembrane protein that consists of an N-terminal PROTEOGLYCAN-like domain, a catalytic region, a single-pass transmembrane domain, and a short intracellular tail. It functions as a dimer and is expressed primarily by cells of the GASTROINTESTINAL TRACT; BILE DUCT EPITHELIUM; and GALL BLADDER. It is expressed at high levels in many solid tumors, especially CLEAR CELL RENAL CARCINOMA, in response to CELL HYPOXIA.

An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)

Treatment using irradiation with LASER light of low power intensity so that the effects are not due to heat, as in LASER THERAPY. These non-thermal effects are thought to be mediated by a photochemical reaction that alters CELL MEMBRANE PERMEABILITY, leading to increased mRNA synthesis and CELL PROLIFERATION. Low-level laser therapy has been used for a wide variety of conditions, but most frequently for wound healing and pain control.

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Searches Linking to this Article